An in vitro cytotoxic assay was also used to reveal if abundant IFNγ secreted by activated commercial PBMCs occurred due to (Z)-BP exposure (Supplemental Figure 3), and we found that high serum IFNγ levels did not affect neurologic function or the general status of the patient (Supplemental Figure 2), and that such levels might convert the cold tumor microenvironment to a “hot” one that is responsive to the synergistic action of PD-L1 inhibitor (pembrolizumab) administration. The gene discussed is IFNG; the disease is neoplasm.